Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-22T16:13:15.636Z Has data issue: false hasContentIssue false
  • English
  • Français

Prevalence and Treatment of Drug-Induced Extrapyramidal Symptoms

Published online by Cambridge University Press:  29 January 2018

D. A. W. Johnson
D. A. W. Johnson*
Affiliation:
University Hospital of South Manchester, West Didsbury, Manchester 20
Get access Rights & Permissions [Opens in a new window]

Abstract

A prospective follow-up of schizophrenic patients treated with depot neuroleptic injections demonstrated the variability of the prevalence rate of morbidity from drug-induced extrapyramidal symptoms. Factors influencing this morbidity are discussed. This study suggests that the need for the treatment of drug-induced symptoms by the use of antiparkinsonian drugs is less than commonly accepted. It is suggested that our psychological set to the problem of drug-induced side-effects requires revision, and in particular that the prescription of anticholinergic drugs needs justification.

Type
Papers
Information
The British Journal of Psychiatry , Volume 132 , Issue 1 , January 1978 , pp. 27 - 30
Copyright
Copyright © Royal College of Psychiatrists, 1978 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ananth, J. V., Horodesky, J., Lechman, H. E. & Bon, T. A. (1970) Effect of withdrawal on chronically hospitalized psychiatric patients. Laval Medical, 41, 934–8.Google ScholarPubMed
Ayd, F. J. (1961) A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association, 174, 1054–60.Google Scholar
Ayd, F. J. (1974) International Drug Therapy Newsletter, ix, 8.Google Scholar
Chan, T. L., Sakalis, G. & Gershon, S. (1973) Some aspects of chlorpromazine metabolism in humans. Clinical Pharmacology and Therapeutics, 14, 133.Google Scholar
Chien, C. P., Dimascio, A. & Cole, J. O. (1974) Antiparkinsonian agents and depot phenothiazine. American Journal of Psychiatry, 131, 86–90.Google Scholar
Daniel, G. R. (1976) Assessment of depot neuroleptics. British Journal of Clinical Pharmacology, Supplement, 3, 417–21.Google Scholar
Ekdawi, M. Y. & Fowke, R. (1966) A controlled trial of anti-parkinsonian drugs in drug-induced parkinsonism. British Journal of Psychiatry, 112, 633–6.Google Scholar
Gerlach, J., Reisby, N. & Randrup, A. (1974) Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacologia, Berlin, 34, 21–35.Google Scholar
Johnson, D. A. W. (1972) The psychiatric side-effects of drugs. The Practitioner, 209, 320–6.Google Scholar
Johnson, D. A. W. (1973) The side-effects of fluphenazine decanoate. British Journal of Psychiatry, 123, 519–22.Google Scholar
Johnson, D. A. W. (1975) Observations on the dose regimes of fluphenazine decanoate in maintenance therapy of schizophrenia. British Journal of Psychiatry, 126, 457–61.Google Scholar
Johnson, D. A. W. (1976) Assessment of drugs in schizophrenia: diagnosis and patient selection. British Journal of Clinical Pharmacology, Supplement, 3, 371–4.Google Scholar
Johnson, D. A. W. (1976) The expectation of outcome from maintenance therapy in chronic schizophrenic patients. British Journal of Psychiatry, 128, 246–50.Google Scholar
Johnson, D. A. W. & Malik, N. A. (1975) A double-blind comparison of fluphenazine decanoate and flupenthixol decanoate in the treatment of acute schizophrenia. Acta Psychiatrica Scandinavica, 51, 257–67.Google Scholar
Kazamatsuri, H., Chien, C. P. & Cole, J. O. (1972) Therapeutic approaches to tardive dyskinesia. Archives of General Psychiatry, 27, 491–9.Google Scholar
Kennedy, P. F., Hershon, H. I. & McGuire, R. G. (1971) Extrapyramidal disorders after prolonged phenothiazine therapy. British Journal of Psychiatry, 118, 509–18.Google Scholar
Klett, C. J. & Caffey, E. (1972) Evaluating the long term need for anti-parkinson drugs by chronic schizophrenics. Archives of General Psychiatry, 26, 374–9.Google Scholar
Loga, S., Curry, S. & Lader, M. (1975) Interaction of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man. British Journal of Clinical Pharmacology, 2, 197–208.CrossRefGoogle ScholarPubMed
Marsden, C. D. (1975) The neuropharmacology of abnormal involuntary movement disorders. In Modern Trends in Neurology, pp 141–57. London: Butterworths Google Scholar
McClelland, H. A., Blessed, G., Bhate, S., Ali, N. & Clarke, P. A. (1974) The abrupt withdrawal of anti-parkinson drugs in schizophrenic patients. British Journal of Psychiatry, 124, 151–9.Google Scholar
McClelland, H. A. (1976) Discussion on assessment of drug-induced extrapyramidal reactions. British Journal of Clinical Pharmacology, Supplement, 3, 401–3.Google ScholarPubMed
Mindham, R. H. S., Gaind, R., Anstee, B. H. & Rimmer, L. (1972) Comparison of amantidine, orphenadrine and placebo in the control of phenothiazine-induced parkinsonism. Psychological Medicine, 2, 406–13.Google Scholar
Mindham, R. H. S. (1976) Assessment of drug-induced extrapyramidal reactions. British Journal of Clinical Pharmacology, 3, 395–400.Google Scholar
Rivera-Calimlim, L. (1976) Impaired absorption of chlorpromazine in rats given trihexyphenidyl. British Journal of Pharmacology, 56, 301–5.CrossRefGoogle ScholarPubMed
Rivera-Calimlim, L., Castaneda, L. & Lasagna, L. (1973) Effects on mode of management on plasma chlorpromazine in psychiatric patients. Clinical Pharmacology and Therapeutics, 14, 978–86.Google Scholar
Rivera-Calimlim, L., Narallah, H., Strauss, J. & Lasagna, L. (1976) Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels. American Journal of Psychiatry, 133, 646–52.Google Scholar
Simpson, G. M. (1970) Controlled studies of anti-parkinson agents in the treatment of drug-induced extrapyramidal symptoms. Acta Psychiatrica Scandinavica, Suppl, 212, 44–51.Google Scholar
Singh, M. M. & Smith, J. (1973) Reversal of some therapeutic effects of an antipsychotic agent by an antiparkinson drug. Journal of Nervous and Mental Diseases, 157, 50–7.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.